KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Non-Current Assets (2016 - 2026)

Bristol Myers Squibb has reported Non-Current Assets over the past 18 years, most recently at $59.3 billion for Q1 2026.

  • Quarterly Non-Current Assets fell 3.85% to $59.3 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $242.6 billion through Mar 2026, down 5.89% year-over-year, with the annual reading at $60.6 billion for FY2025, 3.46% down from the prior year.
  • Non-Current Assets was $59.3 billion for Q1 2026 at Bristol Myers Squibb, down from $60.6 billion in the prior quarter.
  • Over five years, Non-Current Assets peaked at $72.9 billion in Q1 2022 and troughed at $59.3 billion in Q1 2026.
  • The 5-year median for Non-Current Assets is $65.4 billion (2023), against an average of $65.6 billion.
  • Year-over-year, Non-Current Assets fell 14.55% in 2022 and then increased 4.71% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $69.5 billion in 2022, then decreased by 8.85% to $63.4 billion in 2023, then decreased by 0.89% to $62.8 billion in 2024, then decreased by 3.46% to $60.6 billion in 2025, then decreased by 2.28% to $59.3 billion in 2026.
  • Per Business Quant, the three most recent readings for BMY's Non-Current Assets are $59.3 billion (Q1 2026), $60.6 billion (Q4 2025), and $61.3 billion (Q3 2025).